A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)

被引：0
|
作者：
Yoneyama, Koichiro [1 ]
Fukazawa-Shinotsuka, Mizuki [1 ]
Saito, Tomohisa [1 ]
机构：
[1] Chugai Pharmaceut Co Ltd, Tokyo, Japan
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-155934
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2740 / 2741
页数：2
相关论文
共 50 条
  • [1] Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
    Shima, Midori
    Suzuki, Nobuaki
    Nishikii, Hidekazu
    Amano, Kagehiro
    Ogawa, Yoshiyuki
    Kobayashi, Ryota
    Ozaki, Ryoto
    Yoneyama, Koichiro
    Mizuno, Narumi
    Sakaida, Emiko
    Saito, Makoto
    Okamura, Takashi
    Ito, Toshihiro
    Hattori, Norimichi
    Higasa, Satoshi
    Seki, Yoshinobu
    Nogami, Keiji
    THROMBOSIS AND HAEMOSTASIS, 2024,
  • [2] A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A
    Shima, Midori
    Amano, Kagehiro
    Ogawa, Yoshiyuki
    Yoneyama, Koichiro
    Ozaki, Ryoto
    Kobayashi, Ryota
    Sakaida, Emiko
    Saito, Makoto
    Okamura, Takashi
    Ito, Toshihiro
    Hattori, Norimichi
    Higasa, Satoshi
    Suzuki, Nobuaki
    Seki, Yoshinobu
    Nogami, Keiji
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (03) : 534 - 545
  • [3] Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study
    Nishikii, Hidekazu
    Suzuki, Nobuaki
    Kobayashi, Ryota
    Mizuno, Narumi
    Ozaki, Ryoto
    Shima, Midori
    BLOOD, 2022, 140 : 2724 - 2725
  • [4] Bleeding control with emicizumab in patients with acquired hemophilia a
    Ksayer, R.
    Zakharia, K.
    Janbain, M.
    Leissinger, C.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 367 : S176 - S177
  • [5] Should emicizumab be used in patients with acquired hemophilia A?
    Tiede, Andreas
    Kemkes-Matthes, Bettina
    Knoebl, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (03) : 637 - 644
  • [6] Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review
    Ikbel, Ghachem
    Hela, Baccouche
    Yassine, Kaabar Mohamed
    Hamida, Khemiri
    Kamel, Ben Salem
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
  • [7] A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial
    Jackson, KA
    Rosenbaum, SE
    Kerr, BM
    Pithavala, YK
    Yuen, G
    Dudley, MN
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) : 1832 - 1837
  • [8] Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
    Sylvie Retout
    Christophe Schmitt
    Claire Petry
    François Mercier
    Nicolas Frey
    Clinical Pharmacokinetics, 2020, 59 : 1611 - 1625
  • [9] Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
    Retout, Sylvie
    Schmitt, Christophe
    Petry, Claire
    Mercier, Francois
    Frey, Nicolas
    CLINICAL PHARMACOKINETICS, 2020, 59 (12) : 1611 - 1625
  • [10] Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials
    Jimenez-Yuste, Victor
    Oldenburg, Johannes
    Tzeng, Eunice
    Lim, Elise
    Sanabria, Fabian
    Mahlangu, Johnny
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (03)
12345